Fresenius Kabi

Recent Articles

• Insight on First approved COVID-19 vaccine Sputnik V
• Novavax and Serum Institute of India – licensing agreement for Development and Commercial Collaboration
• Novavax reports positive results from phase 1 trial of COVID-19 vaccine candidate, NVX-CoV2373 with Matrix-M
• Lupin gets exclusive rights to market and distribute 2 complex injectable assets from ForDoz Pharma
• Biotricity receives US FDA 510(k) clearance for Bioflux software II system
• Cofsils brand expansion with face masks launch
• Zydus Cadila’s ZyCoV-D in Phase II clinical trials for COVID-19
• Lynk Pharmaceuticals enters exclusive licensing agreements with Kobe University and with RIKEN Research Institute to develop RAS inhibitors with a novel MOA
• Novavax, FDB agreement for large scale manufacturing of COVID-19 vaccine candidate
• Pfizer-BioNTech agreement with U.S. Gov for up to 600 million doses of mRNA-based vaccine aandidate against SARS-CoV-2
• Insight on Novartis’s first-of-its-kind not-for-profit medicine portfolio for symptomatic treatment of COVID-19
• Pfizer and BioNTech announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based SARS-CoV-2 vaccine
• Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial published in The Lancet Journal
• DCGI approved Itolizumab to treat COVID-19 patients with moderate to severe acute respiratory distress 
• Aurobindo Pharma hives off its biosimilars business to subsidiary CuraTeQ Biologics
• Lupin, Mylan receive EUmarketing authorization for Nepexto
• AstraZeneca, Accent Therapeutics partners to develop transformative therapeutics targeting RMPs to treat cancer
• Roche’s Elecsys IL-6 test received USFDA EUA
• Gilead’s Voluntary Licensing Agreements for Remdesivir with 5 generic companies
• Market Exclusivity Case Study: XIFAXAN (rifaximin)